Evidence map›Paper›PMID 29988573›Full record

ArticleFrontiers in immunology2018

Impaired Cell Viability and Functionality of Hepatocytes After Incubation With Septic Plasma-Results of a Second Prospective Biosensor Study.

Martin Sauer, Cristof Haubner, Georg Richter, Johannes Ehler, Thomas Mencke, Steffen Mitzner, Stefan Margraf, Jens Altrichter, Sandra Doß, Gabriele Nöldge-Schomburg

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Martin SauerDepartment of Anesthesiology and Intensive Care Medicine, University Hospital of Rostock, Rostock, Germany.
Cristof HaubnerDepartment of Anesthesiology and Intensive Care Medicine, University Hospital of Rostock, Rostock, Germany.
Georg RichterDepartment of Anesthesiology and Intensive Care Medicine, University Hospital of Rostock, Rostock, Germany.
Johannes EhlerDepartment of Anesthesiology and Intensive Care Medicine, University Hospital of Rostock, Rostock, Germany.
Thomas MenckeDepartment of Anesthesiology and Intensive Care Medicine, University Hospital of Rostock, Rostock, Germany.
Steffen MitznerExtracorporeal Immunomodulation (EXIM), Fraunhofer Institute for Cell Therapy and Immunology, Rostock, Germany.
Stefan MargrafExtracorporeal Immunomodulation (EXIM), Fraunhofer Institute for Cell Therapy and Immunology, Rostock, Germany.
Jens AltrichterDivision of Nephrology, Department of Medicine, University Hospital of Rostock, Rostock, Germany.
Sandra DoßDepartment of Anesthesiology and Intensive Care Medicine, University Hospital of Rostock, Rostock, Germany.
Gabriele Nöldge-SchomburgDepartment of Anesthesiology and Intensive Care Medicine, University Hospital of Rostock, Rostock, Germany.
University of Rostock · DEFraunhofer Institute for Cell Therapy and Immunology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver dysfunction (LD) and liver failure are associated with poor outcome in critically ill patients. In patients with severe sepsis or septic shock, LD occurred in nearly 19% of patients. An early diagnosis of LD at time of initial damage of the liver can lead to a better prognosis of these patients because an early start of therapy is possible. We performed a second prospective study with septic patients to test a new cell-based cytotoxicity device (biosensor) to evaluate clinical relevance for early diagnosis of LD and prognostic capacity. In the clinical study, 99 intensive care unit patients were included in two groups. From the patients of the septic group (

Indexed as

biosensing techniquescytotoxicityhepatocytesinflammationliver failure

Identifiers

PMID29988573
PMCPMC6026797
OpenAlexW2808196948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.